Imagion Biosystems Ltd has released a press release.
Appendix 4C and Quarterly Activities Report - December 2025
Filed with ASX ·
6ix hasn’t read this filing yet.
Imagion Biosystems Ltd. on 6ix
Story so far
Earlier from Imagion Biosystems
- Mercer Convertible Securities Conversion and Amendment
- Positive Final WSU Trial Results To Support IND Submission
- Positive Results Received from WSU on MagSense Dosage
- Appendix 4C and Quarterly Activities Report - September 2025
- Imagion Biosystems HER2 Breast Cancer Program Update
Later from Imagion Biosystems
- IBX's IND Application Lodged with FDA for HER2 Phase 2 Trial
- Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent
- FY25 Appendix 4E and Annual Report
- Appendix 4C and Quarterly Activities Report - March 2026
- Imagion Biosystems Receives IND Clearance from US FDA
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems